China (Mainland)
Diamondsupplier 
Factory Supply Dasatinib monohydrate powder CAS 863127-77-9 CAS NO.863127-77-9
- FOB Price: USD: 500.00-500.00 /Kilogram Get Latest Price
- Min.Order: 10 Gram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Available Specifications:
99%(500-1000)Kilogram
- Product Details
Keywords
- Dasatinib
- Dasatinib monohydrate
- Dasatinib monohydrate powder
Quick Details
- ProName: Factory Supply Dasatinib monohydrate p...
- CasNo: 863127-77-9
- Molecular Formula: C22H28ClN7O3S
- Appearance: white powder
- Application: CML
- DeliveryTime: in 7 days
- PackAge: 100G/bag
- Port: Shanghai/Beijing/Tianjin
- ProductionCapacity: 10 Metric Ton/Year
- Purity: 99%
- Storage: room temperature
- Transportation: Regular transportation
- LimitNum: 10 Gram
- Related Substances: 0.1%
- Residue on Ignition: 0.5%
- Heavy Metal: 10ppm
- Valid Period: 2 years
Superiority
Why is SINOWAY:
1) Specialized in pharmaceutical and healthcare industrial for 34 years.
2) ISO 9001:2015 & SGS audited supplier .
3) Accept various payment terms : T.T 30-60 days.
4) We have warehouse in USA with quickly shipment .
5) We can do different terms of FOB ,CIF/CIP ,DDP ...
Our Advantange of
Why is SINOWAY:
1) Specialized in pharmaceutical and healthcare industrial for 34 years.
2) ISO 9001:2015 & SGS audited supplier .
3) Accept various payment terms : T.T 30-60 days.
4) We have warehouse in USA with quickly shipment .
5) We can do different terms of FOB ,CIF/CIP ,DDP ..
.
Our Advantange of Dasatinib monohydrate powder:
Best Quality and competitive price and enought stock
Details
Basic infomation of Dasatinib monohydrate powder CAS 863127-77-9
| Name | Dasatinib monohydrate |
| CAS | 863127-77-9 |
| MF | C22H28ClN7O3S |
COA of Dasatinib monohydrate powder CAS 863127-77-9
Use of Dasatinib monohydrate powder CAS 863127-77-9
Dasatinib is indicated for adult patients with chronic myelogenous leukemia who have been treated with Imatinibmesylate/Gleevec resistance or intolerance in all phases (chronic, accelerated, Chemicalbook and myeloid).At the same time, the FDA has approved dasatinib under normal procedures for the treatment of adult Patients with Philadelphia chromosomal positive acute lymphoblastic leukemia who are resistant or intolerant to other therapies.
